1
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Improvement of microvascular complications in STZ-diabetic rats treated with Pterocarpus erinaceus Poir. extract

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Pterocarpus erinaceus Poir. from Fabaceae family is a medicinal plant traditionally used in decoction or infusion to treat diabetes mellitus. Although this plant is used in treating diabetes, studies on the effectiveness of its stem bark on the complications induced by chronic hyperglycemia have not been thoroughly addressed. Thus, this study was conducted to prove the efficacy of hydroethanolic extract of stem bark of P. erinaceus on type 2 diabetes and its complications, such as renal fibrosis and retinopathy in rats. STZ diabetics. The dry extract of P. erinaceus stem bark was obtained following the hydroethanolic extraction (v/v). Diabetes was induced with streptozocin in SD rats pretreated with fructose-lard for 20 days. Then, the serum and urinary biochemical parameters were evaluated at the start and the end of the treatment. Rats with blood glucose ≥350 mg/dL and significant proteinuria were selected and treated with P. erinaceus stem bark extract and glibenclamide for 3 weeks. A complete blood count and a histopathological examination of the retina and kidneys were performed at the end of the 41st day of treatment. The results showed that P. erinaceus extract at a dose of 500 mg/kg bw and glibenclamide at a dose of 0.6 mg/kg bw caused a significant decrease (p < 0.0001) in basal blood glucose in STZ diabetic rats during treatment and improved oral glucose intolerance. At the end of the experiment, the treated rats showed a normalization in body weight, food and water consumption. Evaluating of biochemical parameters showed a significant (p < 0.001) decrease in total cholesterol, LDL-C, triglycerides, TG/HDL-C ratio, CPK and oxidative stress in treated rats. No retinal and kidney abnormalities were observed on histological sections in rats treated with plant extract and glibenclamide. In contrast, macular edema and renal fibrosis were observed in the diabetic control group. The findings showed that extract at a dose of 500 mg/kg bw improves oral glucose intolerance, and inhibits lipid deposition and retinal and renal fibrosis. Therefore, the plant extract could be exploited in the production of herbal medicines to manage diabetes and its complications.

          Graphical abstract

          Highlights

          • In vivo study of microvascular complications in a type 2 diabetes model for 41 days.

          • Induction of metabolic syndrome and diabetic complications for 20 days in rats.

          • Treatment of complications in STZ diabetic rats for 3 weeks with P. erinaceus Poir.

          • Treatment improves insulin resistance and lipid profile.

          • Treatment eventually reversed renal fibrosis and retinopathy.

          Related collections

          Most cited references50

          • Record: found
          • Abstract: not found
          • Article: not found

          A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding

            Bookmark
            • Record: found
            • Abstract: not found
            • Article: not found

            Tissue sulfhydryl groups

              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Diabetic Kidney Disease: Challenges, Progress, and Possibilities.

              Diabetic kidney disease develops in approximately 40% of patients who are diabetic and is the leading cause of CKD worldwide. Although ESRD may be the most recognizable consequence of diabetic kidney disease, the majority of patients actually die from cardiovascular diseases and infections before needing kidney replacement therapy. The natural history of diabetic kidney disease includes glomerular hyperfiltration, progressive albuminuria, declining GFR, and ultimately, ESRD. Metabolic changes associated with diabetes lead to glomerular hypertrophy, glomerulosclerosis, and tubulointerstitial inflammation and fibrosis. Despite current therapies, there is large residual risk of diabetic kidney disease onset and progression. Therefore, widespread innovation is urgently needed to improve health outcomes for patients with diabetic kidney disease. Achieving this goal will require characterization of new biomarkers, designing clinical trials that evaluate clinically pertinent end points, and development of therapeutic agents targeting kidney-specific disease mechanisms (e.g., glomerular hyperfiltration, inflammation, and fibrosis). Additionally, greater attention to dissemination and implementation of best practices is needed in both clinical and community settings.
                Bookmark

                Author and article information

                Contributors
                Journal
                Biochem Biophys Rep
                Biochem Biophys Rep
                Biochemistry and Biophysics Reports
                Elsevier
                2405-5808
                02 September 2023
                September 2023
                02 September 2023
                : 35
                : 101541
                Affiliations
                [1]Pathophysiology, Bioactive Substances and Safety Research Unit, Faculty of Sciences, University of Lome, Postbox 1515, Togo
                Author notes
                []Corresponding author. Department of Animal Physiology, Faculty of Sciences, University of Lome, Postbox 1515, Lome, Togo. n.k.atchou@ 123456gmail.com
                Article
                S2405-5808(23)00122-X 101541
                10.1016/j.bbrep.2023.101541
                10477066
                37674975
                668fc64e-b37b-4003-adff-bf47c6238bab
                © 2023 The Authors

                This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).

                History
                : 8 July 2023
                : 8 August 2023
                : 30 August 2023
                Categories
                Research Article

                pterocarpus erinaceus,diabetes,microvascular complications,lipid profile,renal fibrosis,retinopathy

                Comments

                Comment on this article